/
GMAB
$27.47+$1.45 (+5.57%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$16.0B
614M shares
52-week range
$20.23 – $35.43
48% from low
Exchange
NASDAQ
ADRC
Borrow rate
0.60%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-14.08
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.03B | $5.37B | $10.11B | $8.42B | $14.51B | $16.47B | $21.53B | $3.72B |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $226.0M | $985.0M | $309.2M |
| Gross profit | $3.03B | $5.37B | $10.11B | $8.42B | $14.51B | $16.25B | $20.54B | $3.41B |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 98.6% | 95.4% | 91.7% |
| R&D | $1.43B | $2.39B | $3.14B | $4.18B | $5.56B | $7.63B | $9.75B | $1.56B |
| Operating income | $1.38B | $2.64B | $6.31B | $2.95B | $6.27B | $5.32B | $6.70B | $1.25B |
| EBITDA | $1.70B | $3.00B | $6.16B | $4.18B | $7.35B | $5.95B | $9.70B | $1.34B |
| Net income | $1.47B | $2.17B | $4.76B | $2.96B | $5.45B | $4.35B | $7.84B | $963.8M |
| Net margin | 48.7% | 40.4% | 47.1% | 35.1% | 37.6% | 26.4% | 36.4% | 25.9% |
| EPS (diluted) | 2.37 | 3.40 | 7.22 | 4.48 | 8.26 | 6.60 | 12.14 | 1.54 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4.3B | $1.14 | $0.96–$1.38 | 9 |
| 2027 | $5.1B | $1.70 | $1.15–$2.20 | 9 |
| 2028 | $6.1B | $2.54 | $1.58–$3.34 | 16 |
| 2029 | $6.1B | $2.49 | $2.29–$2.77 | 14 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$6.25
Price
$27.47
Implied downside
-77%
Peer comparison
Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
www.genmab.com- Employees
- 3,088
- IPO / List date
- Oct 5, 2010
Held by traders on TradeandTell
No one on the platform currently holds GMAB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 4,414,550 | $118.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded GMAB yet.
